A5072606116- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Complement system in diseases
- SARS-CoV-2 and COVID-19 Research
- Hematopoietic Stem Cell Transplantation
- COVID-19 Clinical Research Studies
- Plant and animal studies
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pharmaceutical industry and healthcare
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Lichen and fungal ecology
- Cutaneous lymphoproliferative disorders research
- Multiple Myeloma Research and Treatments
- Autoimmune Bullous Skin Diseases
- Phytochemical compounds biological activities
- Fermentation and Sensory Analysis
- Chronic Lymphocytic Leukemia Research
University of Rome Tor Vergata
2016-2024
Dana-Farber Cancer Institute
2005
Complement C3 activation contributes to COVID-19 pathology, and targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating inhibitor, AMY-101, in severe (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 ( n = 16) or placebo 15) addition standard of care. was safe well tolerated. Compared (8 15, 53.3%), higher, albeit nonsignificant, proportion AMY-101–treated patients (13 16, 81.3%) were free supplemental oxygen at...
Given the selection of elderly patients with AML in first complete remission (CR1) advantage consolidation allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed CR1 aged 60-75 years were registered and a donor search initiated. After one cycle, matched randomized to HCT fludarabine/lowdose total body irradiation cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free...
Background: The hidden nature of the use opioids, amphetamines, cocaine, and cannabis (the most commonly used studied illicit drugs) precludes accurate estimation how many people them further important aspects use. Among drug use, permanence times in specific using states related to lifestyles various sub populations users are interest, per se, as essential components estimates relating prevalence incidence for evaluating policies. Methods: Several administrative databases surveys collected...